U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07398417) titled 'Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design' on Feb. 04.
Brief Summary: The study is a Phase 3, double-blind, placebo-controlled, randomized withdrawal study to assess the efficacy and safety of AXS-14 in the management of fibromyalgia.
Study Start Date: Jan. 14
Study Type: INTERVENTIONAL
Condition:
Fibromyalgia
Intervention:
DRUG: AXS-14 (Esreboxetine)
AXS-14 tablets taken once daily
DRUG: Placebo
Placebo tablets taken once daily
Recruitment Status: RECRUITING
Sponsor: Axsome Therapeutics, Inc.
Disclaimer: Curated by HT Syndication....